Anhui Anke BioTech Group (300009) - Total Liabilities
Based on the latest financial reports, Anhui Anke BioTech Group (300009) has total liabilities worth CN¥755.64 Million CNY (≈ $110.57 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Anhui Anke BioTech Group - Total Liabilities Trend (2006–2024)
This chart illustrates how Anhui Anke BioTech Group's total liabilities have evolved over time, based on quarterly financial data. See 300009 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Anhui Anke BioTech Group Competitors by Total Liabilities
The table below lists competitors of Anhui Anke BioTech Group ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shunsin Technology Holdings Ltd
TW:6451
|
Taiwan | NT$12.08 Billion |
|
Wuxi Boton Technology Co Ltd
SHE:300031
|
China | CN¥2.15 Billion |
|
Nanjing Gaoke Co Ltd
SHG:600064
|
China | CN¥19.44 Billion |
|
Zen Technologies Limited
NSE:ZENTEC
|
India | Rs2.08 Billion |
|
Ningbo PIA Automation Holding Corp. A
SHG:688306
|
China | CN¥3.34 Billion |
|
Charter Hall Long Wale REIT
AU:CLW
|
Australia | AU$2.01 Billion |
|
AG Anadolu Group Holding
IS:AGHOL
|
Turkey | TL348.37 Billion |
|
Taiwan Cogeneration Corp
TW:8926
|
Taiwan | NT$15.02 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Anhui Anke BioTech Group's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Anhui Anke BioTech Group (300009) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anhui Anke BioTech Group's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anhui Anke BioTech Group (2006–2024)
The table below shows the annual total liabilities of Anhui Anke BioTech Group from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥835.41 Million ≈ $122.25 Million |
-17.97% |
| 2023-12-31 | CN¥1.02 Billion ≈ $149.03 Million |
+19.31% |
| 2022-12-31 | CN¥853.62 Million ≈ $124.91 Million |
+11.51% |
| 2021-12-31 | CN¥765.52 Million ≈ $112.02 Million |
+32.84% |
| 2020-12-31 | CN¥576.29 Million ≈ $84.33 Million |
+9.52% |
| 2019-12-31 | CN¥526.19 Million ≈ $77.00 Million |
+2.00% |
| 2018-12-31 | CN¥515.86 Million ≈ $75.49 Million |
+4.48% |
| 2017-12-31 | CN¥493.73 Million ≈ $72.25 Million |
-8.41% |
| 2016-12-31 | CN¥539.04 Million ≈ $78.88 Million |
+293.98% |
| 2015-12-31 | CN¥136.82 Million ≈ $20.02 Million |
-3.72% |
| 2014-12-31 | CN¥142.11 Million ≈ $20.79 Million |
+59.29% |
| 2013-12-31 | CN¥89.21 Million ≈ $13.05 Million |
+22.37% |
| 2012-12-31 | CN¥72.91 Million ≈ $10.67 Million |
+21.98% |
| 2011-12-31 | CN¥59.77 Million ≈ $8.75 Million |
-11.12% |
| 2010-12-31 | CN¥67.25 Million ≈ $9.84 Million |
+43.24% |
| 2009-12-31 | CN¥46.95 Million ≈ $6.87 Million |
-36.83% |
| 2008-12-31 | CN¥74.32 Million ≈ $10.88 Million |
-25.28% |
| 2007-12-31 | CN¥99.46 Million ≈ $14.55 Million |
-4.11% |
| 2006-12-31 | CN¥103.72 Million ≈ $15.18 Million |
-- |
About Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterf… Read more